<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318354</url>
  </required_header>
  <id_info>
    <org_study_id>OLME/10/026</org_study_id>
    <nct_id>NCT03318354</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fasted Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets
      40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were
      separated by a washout period of 7 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose
      Bioequivalence Study of Olmesartan Medoxomil Tablets containing Olmesartan Medoxomil 40 mg
      (Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Benicar® 40 mg Tablets
      containing Olmesartan Medoxomil 40 mg (Reference, Daiichi Sankyo Inc.,USA) in Healthy Human
      Volunteers Under Fasting Condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre dose to 72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Pre dose to 72 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torrent's Olmesartan Medoxomil Tablets 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daiichi Sankyo Inc's Benicar Tablets 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Olmesartan Medoxomil Tablets 40 mg</intervention_name>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daiichi Sankyo Inc's Benicar Tablets 40 mg</intervention_name>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males with age between 18-45 years (both inclusive)

          -  Weight equal to or more than 50.00 Kgs

          -  BMI 18.50 - 24.90 Kg/m2

          -  Healthy as determined by medical history, clinical and laboratory examination
             performed within 21 days prior to admission day for the first period of the study.

          -  Must have provided written informed consent for participation in the study in the
             subject's vernacular language

          -  In the opinion of the Principal Investigator/Designee, be able to comply with the
             study procedures and protocol restrictions.

        Exclusion Criteria:

          -  Known hypersensitivity or idiosyncratic reaction to Olmesartan, its excipients or
             similar classes of drugs

          -  Any evidence of significant abnormalities upon physical or clinical examination

          -  Sitting blood pressure less than 100/70 mm Hg or more than 140/90 mm Hg and radical
             pulse rate less than 60 mm Hg or more than 100 mm Hg per minute at the time of
             screening.

          -  Laboratory values, which are significantly different from predefined reference ranges
             and judged clinically significant.

          -  Any clinically significant abnormality in ECG.

          -  Any clinically significant abnormality in Chest X-ray (PA view)

          -  Regular use of tobacco or nicotine in significant amount in any form (e.g. use of more
             than 10 cigarettes a day) or have difficulty in abstaining from [smoking] nicotine use
             for the duration of the study period.

          -  History of drug dependence or excessive alcohol intake [subjects who drink more than 2
             units per day (30 ml of 40% alcohol) or more than 14 units per week] on a habitual
             basis, or inability to abstain from alcohol for the duration of study period.

          -  History or presence of serious gastrointestinal, liver, kidney, heart, lung,
             neurological or blood disease, diabetes or glaucoma.

          -  History or presence of any chronic illnesses such as arthritis, asthma, epilepsy,
             hypertension etc.

          -  Presence of disease markers of HIV 1 OR 2, Hepatitis B or C Viruses and VDRL.

          -  Positive result for drug(s) of abuse testing (amphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine and opioids) in urine.

          -  Positive test for alcohol breath analyzer test.

          -  History and presence of any psychiatric illness.

          -  History and presence of any illness including allergic skin diseases, allergic asthma
             and drug-induced allergy, e.g. NSAIDs

          -  History of significant blood loss (≥ 350 mL) due to any reason, including blood
             donation within last 12 weeks prior to screening.

          -  Existence of any surgical or medical condition which in the judgment of Principal
             Investigator/ Designee might interfere with the absorption, distribution, metabolism
             or excretion of the study drug, or, is likely to compromise the safety of subject.

          -  Intake of any enzyme-modifying drugs such as cimetidine, theophylline,
             benzodiazepines, ranitidine, proton pump inhibitors, erythromycin, diuretics,
             ketoconazole, anti hypertensive drugs, dopamine agonists, etc within 30 days of study
             drug administration, or administration/ intake of any prescription or OTC drug
             including vitamins and natural supplements within 30 days of study drug
             administration. In such cases, enrolment of the subject in the study will be at the
             discretion of the Principal Investigator/designee.

          -  Intake of unusual diet (e.g. low sodium) for two weeks prior to screening and
             throughout the subject's participation the study. In such case, subject selection will
             be at the discretion of the Principal investigator/ designee.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

